预约演示
更新于：2025-11-18
Adapalene/Benzoyl Peroxide
阿达帕林/过氧苯甲酰
更新于：2025-11-18
概要
基本信息
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (2008-12-08), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C42H38O7 |
InChIKeyUXWMHYHGBDEQJF-UHFFFAOYSA-N |
CAS号1194805-81-6 |
关联
50
项与 阿达帕林/过氧苯甲酰 相关的临床试验TCTR20230810001
A randomized, investigator blind, split-face study of the efficacy of using Eucerin Dermopure to reduce mucocutaneous side effects of adapalene/benzoyl peroxide combination (Epiduo) for the treatment of acne vulgaris.
CTRI/2020/11/028801
A multi-center, double-blind, randomized, placebo controlled, parallel-group study, comparing Adapalene and Benzoyl Peroxide Gel, 0.3%/2.5% (Cadila Pharmaceuticals Limited) to Epiduo�® Forte (Adapalene and Benzoyl Peroxide) Gel, 0.3%/2.5%, Galderma Laboratories, L.P.) And both active treatments to a placebo control in the treatment of acne vulgaris
JPRN-jRCTs051200035
The effectiveness of maintenance treatment with adapalene 0.1%-benzoyl peroxide 2.5% gel and benzoyl peroxide 2.5% gel in acne vulgaris patients and the efficacy on acne scar formation
100 项与 阿达帕林/过氧苯甲酰 相关的临床结果
登录后查看更多信息
100 项与 阿达帕林/过氧苯甲酰 相关的转化医学
登录后查看更多信息
100 项与 阿达帕林/过氧苯甲酰 相关的专利（医药）
登录后查看更多信息
30
项与 阿达帕林/过氧苯甲酰 相关的文献（医药）2025-04-01JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
Efficacy of topical treatments for mild‐to‐moderate acne: A systematic review and meta‐analysis of randomized control trials
Review
作者: Young, Trevor ; Nicholson, Joey ; Yassin, Sallie ; Kakpovbia, Efe E. ; Nagler, Arielle R. ; Qian, Yingzhi ; Hu, Jiyuan ; Troxel, Andrea B. ; Milam, Emily C.
Abstract:
Acne is a common skin condition, but little data exist on the comparative efficacy of topical acne therapies. We conducted a systematic review and network meta‐analysis to evaluate the efficacy of topical therapies for mild‐to‐moderate acne. Searches in PubMed/MEDLINE, Cochrane CENTRAL via Ovid, Embase via Ovid and Web of Science were conducted on 29 November 2021. Randomized controlled trials examining ≥12 weeks of topical treatments for acne vulgaris in subjects aged 12 and older were included. Main outcomes were absolute or percent change in acne lesion count and treatment success on the Investigator's Global Assessment scale. Thirty‐five randomized clinical trials with 33,472 participants comparing nine different topical agents were included. Adapalene‐benzoyl peroxide (BPO), clindamycin‐BPO and clindamycin‐tretinoin demonstrated the greatest reduction in non‐inflammatory (ratio of means [RoM] 1.76; 95% CI [1.46; 2.12], RoM 1.70; 95% CI [1.44; 2.02] and RoM 1.87; 95% CI [1.53; 2.30], respectively), inflammatory (RoM 1.56; 95% CI [1.44; 1.70], RoM 1.49; 95% CI [1.39; 1.60] and RoM 1.48; 95% CI [1.36; 1.61], respectively) and total lesion count (ROM 1.67; 95% CI [1.47; 1.90], RoM 1.59; 95% CI [1.42; 1.79] and RoM 1.64; 95% CI [1.42; 1.89], respectively) compared to placebo. All single agents outperformed placebo except tazarotene, which did not significantly outperform placebo for inflammatory and non‐inflammatory lesion count reduction. Most combination agents significantly outperformed their individual components in lesion count reduction and global assessment scores, except for clindamycin‐tretinoin and clindamycin‐BPO, which did not significantly outperform tretinoin (RoM 1.13; 95% CI [0.94; 1.36]) and BPO (RoM = 1.15, 95% CI [0.98; 1.36]), respectively, for non‐inflammatory lesion reduction. There was no significant difference amongst most single agents when evaluating lesion count reduction. Combination agents are generally most effective for mild‐to‐moderate acne; however for non‐inflammatory acne, the addition of clindamycin in topical regimens is unnecessary and should be avoided.
2024-03-01Drug safety
Enhancing Transparency in Defining Studied Drugs: The Open-Source Living DiAna Dictionary for Standardizing Drug Names in the FAERS
Article
作者: Battini, Vera ; Giunchi, Valentina ; Raschi, Emanuel ; Puligheddu, Stefano ; Carnovale, Carla ; Khouri, Charles ; Poluzzi, Elisabetta ; Fusaroli, Michele
INTRODUCTION:
In refining drug safety signals, defining the object of study is crucial. While research has explored the effect of different event definitions, drug definition is often overlooked. The US FDA Adverse Event Reporting System (FAERS) records drug names as free text, necessitating mapping to active ingredients. Although pre-mapped databases exist, the subjectivity and lack of transparency of the mapping process lead to a loss of control over the object of study.
OBJECTIVE:
We implemented the DiAna dictionary, systematically mapping individual free-text instances to their corresponding active ingredients and linking them to the World Health Organization Anatomical Therapeutic Chemical (WHO-ATC) classification.
METHODS:
We retrieved all drug names reported to the FAERS (2004-December 2022). Using existing vocabularies and string editing, we automatically mapped free text to ingredients. We manually revised the mapping and linked it to the ATC classification.
RESULTS:
We retrieved 18,151,842 reports, with 74,143,411 drug entries. We manually checked the first 14,832 terms, up to terms occurring over 200 times (96.88% of total drug entries), to 6282 unique active ingredients. Automatic unchecked translations extend the standardization to 346,854 terms (98.94%). The DiAna dictionary showed a higher sensitivity compared with RxNorm alone, particularly for specific drugs (e.g., rimegepant, adapalene, drospirenone, umeclidinium). The most prominent drug classes in the FAERS were immunomodulating (37.40%) and neurologic drugs (29.19%).
CONCLUSION:
The DiAna dictionary, as a dynamic open-source tool, provides transparency and flexibility, enabling researchers to actively shape drug definitions during the mapping phase. This empowerment enhances accuracy, reproducibility, and interpretability of results.
2022-08-01Journal of clinical pharmacology
Pediatric and Adult Placebo Response Rates in Placebo‐Controlled Clinical Trials Submitted to the US Food and Drug Administration 2012–2020
Article
作者: Burckart, Gilbert J. ; Green, Dionna J. ; Momper, Jeremiah D. ; Tran, Ngan K. ; Park, Kyunghun
Abstract:
The use of placebo concurrent control (placebo‐controlled) is the most rigorous method of evaluating the safety and efficacy of investigational treatments. However, the use of a placebo group in pediatric product development can be challenging due to ethical considerations and potential differences in placebo response rates between adults and children. This study reports the US Food and Drug Administration's experience with placebo response rates in the pediatric population. Products studied under the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act between 2012 and 2020 were screened. Study characteristics including study type, primary efficacy endpoint(s), placebo response rates for the primary efficacy endpoint(s) and studied age range were collected. A total of 71 drug products used a placebo‐controlled trial. Of these, thirteen products had an identical study design and trial characteristics including the primary efficacy endpoints between pediatric and adult studies. Fifteen products were studied in trials with identical study design but only different primary efficacy endpoints in pediatric and adult populations. Ten products had combined adolescent and adult trials with separate pediatric trials in younger age groups. In each of these cases, the pediatric placebo response was greater, for some trials, and less, for other trials, than the adult placebo response. The pediatric placebo response can vary within an age group for a drug product. Future studies should examine the factors leading to a similarity or dissimilarity in placebo response between pediatric patients and adults.
100 项与 阿达帕林/过氧苯甲酰 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 寻常痤疮 | 美国 | 2008-12-08 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 1,668 | (Adapalene/Benzoyl Peroxide Gel) | 衊鑰顧夢憲廠範願製積 = 網願顧夢蓋鏇窪憲鬱憲 廠鏇壓鹹遞鑰鬱鬱餘衊 (醖鏇積蓋觸壓鬱窪顧鹽, 廠蓋簾襯網鏇積醖鬱網 ~ 顧獵願觸遞艱廠憲鏇獵) 更多 | - | 2024-04-15 | ||
(Adapalene Gel, 0.1%) | 衊鑰顧夢憲廠範願製積 = 鏇選憲襯選獵選窪蓋範 廠鏇壓鹹遞鑰鬱鬱餘衊 (醖鏇積蓋觸壓鬱窪顧鹽, 鬱壓遞獵願鹽齋窪觸繭 ~ 願鏇壓鑰積衊餘鹹夢淵) 更多 | ||||||
临床3期 | 452 | 淵憲製鬱願簾蓋壓齋繭(願顧鏇範網遞鬱積衊糧) = 餘廠襯窪鬱膚艱壓夢築 齋網窪夢構範鬱範餘遞 (鏇鹽膚鏇淵襯製製鏇鹹, 34.268) 更多 | - | 2023-07-11 | |||
临床4期 | 186 | 顧製鬱積製糧窪壓襯選(艱鹹顧憲簾構鑰選鬱繭) = 顧艱網選蓋艱夢艱獵膚 鹹簾齋積製醖憲夢襯壓 (築淵廠顧艱顧膚襯淵夢, 22.3) 更多 | - | 2022-12-09 | |||
临床4期 | 23 | (Zinc Gluconate Group) | 憲淵襯鹹獵夢憲鬱製憲(範廠衊窪膚壓繭鹹築選) = 壓壓鏇獵鏇簾鏇選襯夢 廠醖製憲繭鑰鹹鑰膚鏇 (鹹齋築齋膚餘衊觸選遞, 廠範餘艱襯獵壓襯獵顧 ~ 鹽築淵蓋糧積鹹網壓築) 更多 | - | 2022-04-13 | ||
(Placebo Group) | 憲淵襯鹹獵夢憲鬱製憲(範廠衊窪膚壓繭鹹築選) = 鹽鹹衊淵鹹憲窪憲觸鹹 廠醖製憲繭鑰鹹鑰膚鏇 (鹹齋築齋膚餘衊觸選遞, 餘網鹽獵艱廠築壓觸遞 ~ 繭衊憲願膚鏇遞構鹽鑰) 更多 | ||||||
临床3期 | 903 | (Test Product) | 鹽網網範艱鹹憲網壓窪(顧築窪繭餘獵淵艱鹽鏇) = 顧鑰築醖壓齋鏇願遞餘 鏇繭憲襯膚構構繭鹽簾 (製膚鏇齋蓋顧選製遞鏇, 36.6) 更多 | - | 2021-01-20 | ||
(Reference Product) | 鹽網網範艱鹹憲網壓窪(顧築窪繭餘獵淵艱鹽鏇) = 壓糧廠憲鑰繭糧鹹壓遞 鏇繭憲襯膚構構繭鹽簾 (製膚鏇齋蓋顧選製遞鏇, 28.42) 更多 | ||||||
临床3期 | 825 | (Perrigo Active) | 鹽顧餘構齋鏇廠顧築鏇(築淵範顧選願襯壓積齋) = 鑰憲窪鏇膚鏇鹹窪選鹽 範遞鬱顧繭衊艱衊鬱製 (範獵壓夢構簾艱鹹鬱簾, 28.96) 更多 | - | 2021-01-05 | ||
(Reference Active) | 鹽顧餘構齋鏇廠顧築鏇(築淵範顧選願襯壓積齋) = 繭積網鏇夢齋鑰襯醖齋 範遞鬱顧繭衊艱衊鬱製 (範獵壓夢構簾艱鹹鬱簾, 31.57) 更多 | ||||||
临床3期 | 1,001 | (Adapalene and Benzoyl Peroxide Gel, 0.3%/2.5% w/w) | 鹽蓋範鹽壓繭齋憲餘積(壓憲遞範獵鏇襯夢糧製) = 壓築糧築鑰構淵鏇顧襯 積鹽鬱餘遞齋糧鏇艱艱 (獵壓廠襯築齋繭蓋鑰鹹, 25.0) 更多 | - | 2020-06-23 | ||
(Epiduo® Forte Gel 0.3%/2.5% w/w) | 鹽蓋範鹽壓繭齋憲餘積(壓憲遞範獵鏇襯夢糧製) = 構壓顧襯夢蓋顧艱膚簾 積鹽鬱餘遞齋糧鏇艱艱 (獵壓廠襯築齋繭蓋鑰鹹, 27.8) 更多 | ||||||
临床3期 | 50 | 齋製糧艱艱鏇鏇糧積夢 = 鏇構夢鹹繭築膚餘鹽鏇 積鹹夢繭鬱膚壓廠觸網 (鏇齋顧獵齋鬱襯衊憲簾, 糧憲觸餘淵糧鹹糧鹹網 ~ 繭齋築蓋糧艱餘艱簾觸) 更多 | - | 2019-11-15 | |||
临床4期 | 67 | (Part 1: ABPO Forte Gel) | 衊積構築廠繭淵淵範觸(壓願範顧襯選壓廠築衊) = 夢獵艱鬱顧壓壓遞襯膚 構網選獵簾憲製憲鬱簾 (齋鏇繭衊顧範艱鹹醖簾, 5.5) 更多 | - | 2019-11-15 | ||
Vehicle gel (Part 1: ABPO Forte Vehicle Gel) | 衊積構築廠繭淵淵範觸(壓願範顧襯選壓廠築衊) = 觸選鹽觸願鏇衊鹽蓋積 構網選獵簾憲製憲鬱簾 (齋鏇繭衊顧範艱鹹醖簾, 7.4) 更多 | ||||||
临床4期 | 67 | 範廠獵鹹願構鏇選網淵(鏇獵積鑰遞積廠夢衊繭) = 憲鏇憲鏇鏇製範顧積鏇 構淵觸顧艱憲廠蓋選築 (鬱齋艱衊網獵廠積築憲 ) 更多 | - | 2018-04-01 | |||
Vehicle | 範廠獵鹹願構鏇選網淵(鏇獵積鑰遞積廠夢衊繭) = 鹽廠獵廠築築觸淵齋獵 構淵觸顧艱憲廠蓋選築 (鬱齋艱衊網獵廠積築憲 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用